LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A Review on the Comparison of Vemurafenib and Dabrafenib in the treatment of Melanoma caused by Mutation of Braf

Photo from wikipedia

Metastatic melanoma is one of the most aggressive forms of skin cancer. The mortality rate of this cancer is high .Almost 60% of the melanomas are due to the mutation… Click to show full abstract

Metastatic melanoma is one of the most aggressive forms of skin cancer. The mortality rate of this cancer is high .Almost 60% of the melanomas are due to the mutation of BRAF gene. BRAF V600E mutations has been implicated in melanoma genesis by different mechanisms. It occurs due to the improper regulation of the activation of downstream MEK (mitogen activated protein kinase enzyme)/ERK (extra cellular signal related kinase) effectors. In order to overcome the increasing rate of this disease a comparative study has been performed between two ERK/MEK inhibitors namely vemurafenib and dabrafenib and also to understand the relative efficacy and toxicity effect between these two therapeutic modalities.

Keywords: melanoma; braf; review comparison; mutation braf; vemurafenib dabrafenib

Journal Title: Research Journal of Pharmacy and Technology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.